ReviewHerz2021
Vagal stimulation in heart failure.
Review in Herz, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 41 citations in OpenAlex.
- Acute right-sided transcutaneous vagus nerve stimulation improves cardio-vagal baroreflex gain in patients with chronic heart failure.Clinical autonomic research : official journal of the Clinical Autonomic Research Society · 2025Trial
- Heart Meets Brain: Insights into Neurocardiac Pathophysiology.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Review
- The Heart-Brain Axis in the Context of Cardiovascular Disease.Physiology (Bethesda, Md.) · 2026Review
- Vagus nerve stimulation: An update of currently registered clinical trials on ClinicalTrials.gov.Surgical neurology international · 2026Review
- Chronic heart failure and heart transplantation: The relationship between autonomic function and cardiac performance.World journal of transplantation · 2025Review
- Sympathovagal crosstalk: Y2-receptor blockade enhances vagal effects which in turn reduce NPY levels via muscarinic receptor activation.Cardiovascular research · 2025Article
- Phasic effects of cardiac-synchronized vagus nerve stimulation on spatiotemporal behavior of the sinoatrial node in swine.Heart rhythm O2 · 2025Article
- Towards spatially selective efferent neuromodulation: anatomical and functional organization of cardiac fibres in the porcine cervical vagus nerve.The Journal of physiology · 2025Article
- Review
- Selective efferent vagal stimulation in heart failure.Experimental physiology · 2024Review
- Vagal nerve stimulation in myocardial ischemia/reperfusion injury: from bench to bedside.Bioelectronic medicine · 2024Review
- Using neural biomarkers to personalize dosing of vagus nerve stimulation.Bioelectronic medicine · 2024Article
- The Intrinsic Cardiac Nervous System: From Pathophysiology to Therapeutic Implications.Biology · 2024Review
- Vagus Nerve Stimulation for Myocardial Ischemia: The Sooner the Better.JACC. Basic to translational science · 2023Article
- A Comparative Review of Vagal Nerve Stimulation Versus Baroreceptor Activation Therapy in Cardiac Diseases.Cureus · 2023Review
- A novel ex-vivo isolated rabbit heart preparation to explore the cardiac effects of cervical and cardiac vagus nerve stimulation.Scientific reports · 2023Article
- Chronic vagus nerve stimulation in patients with heart failure: challenge or failed translation?Frontiers in cardiovascular medicine · 2023Review
- Non-invasive neuromodulation of the cervical vagus nerve in rare primary headaches.Frontiers in pain research (Lausanne, Switzerland) · 2023Review
- Acetylcholine Reduces L-Type Calcium Current without Major Changes in Repolarization of Canine and Human Purkinje and Ventricular Tissue.Biomedicines · 2022Article
- Current and future use of neuromodulation in heart failureEuropean heart journal supplements : journal of the European Society of Cardiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vagal nerve stimulation (VNS) has a strong pathophysiological rationale as a potentially beneficial treatment for heart failure with reduced ejection fraction. Despite several promising preclinical studies and pilot clinical studies, the two large, controlled trials-NECTAR-HF and INOVATE-HF-failed to demonstrate the expected benefit. It is likely that clinical application of VNS in phase III studies was performed before a sufficient degree of understanding of the complex pathophysiology of autonomic electrical modulation had been achieved, therefore leading to an underestimation of its potential benefit. More knowledge on the complex dose-response issue of VNS (i.e., pulse amplitude, frequency, duration and duty cycle) has been gathered since these trials and a new randomized study is currently underway with an adaptive design and a refined approach in an attempt to deliver the proper dose to a more selected group of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.